[Fabry's disease; towards a treatment].
Fabry's disease, deficiency of the enzyme alpha-galactosidase A, is an X-linked lysosomal storage disorder. Clinical symptoms are caused by continuous deposition of specific glycolipids in endothelial cells, neural cells, skin and cornea. These depositions give rise to skin (angiokeratoma) and eye abnormalities (cornea verticillata), acroparaesthesias and anhidrosis and later in life cause renal insufficiency and cardiovascular complications. Hemizygous males suffer from Fabry's disease, whereas female carriers (heterozygotes) are usually asymptomatic. Recently, an atypical presentation of Fabry's disease was described in males who only presented with cardiac involvement. Therefore, the actual number of Fabry patients in the Netherlands could be higher than the predicted 300. Diagnosis in males can be established by measuring alpha-galactosidase enzyme activity in plasma, leukocytes or fibroblasts. Apart from kidney transplantation only symptomatic therapy is available today. Enzyme supplementation therapy (as shown in Gaucher's disease) and substrate deprivation are possible ways of treatment in the future.
Linthorst
G E
GE
Afd. Inwendige Geneeskunde, onderafd. Klinische Hematologie, Academisch Medisch Centrum, Meibergdreef 9, 1105 AZ Amsterdam. g.e.linthorst@amc.uva.nl
Hollak
C E
CE
Bosman
D K
DK
Heymans
H S
HS
Aerts
J M
JM
D002312:Cardiomyopathy, Hypertrophic / Q000209:etiology*; D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D000795:Fabry Disease / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation; D008297:Male; D009426:Netherlands / Q000453:epidemiology; D051437:Renal Insufficiency / Q000209:etiology*; D013684:Telangiectasis / Q000209:etiology*; D000519:alpha-Galactosidase / Q000627:therapeutic use*
D000519:alpha-Galactosidase